Ménière disease is a disorder of the inner ear, characterized by rotational
vertigo,
hearing loss,
tinnitus, and vegetative symptoms. The aim of the present research is to examine the effectiveness of
betahistine and
piracetam in the reduction of
vertigo attacks in
Ménière disease. To verify our hypothesis, 105 (31 male and 74 females, mean age [standard deviation], 57.4 [11.05]) adult patients with definite
Ménière disease were enrolled in this investigation. Beside the analysis of the hospital records, the subjective complaints of the patients and the completed
vertigo diaries were taken into consideration too. The statistical analysis was completed using the IBM SPSS version 24 software. Retrospective analysis, including a 12 years period was conducted. Based on our results,
betahistine was successful in the reduction of attacks. Statistically significant decrease was achieved in frequency of
dizziness (P = .000331) and
vertigo (P < .00001) and in the duration of them (P = .000098), although in the mean power of them was not (P = .0887). The mean dose in the symptomatic treatment was determined as 87.5 ± 27.2 mg per day; however, there was no connection detected between the dose of the agent and the effectiveness of the symptomatic control. By using dual
therapy (
betahistine and
piracetam),
vertigo episodes appeared significantly less often (P = .027, Odds ratio: 4.9, 95% confidence interval: 1.2-20.2). Finally, it can be concluded that
betahistine is effective in
Ménière disease, but the daily dose of it should be set up for every patient individually. The advantage of the dual
therapy was also confirmed.